医学
雷洛昔芬
类风湿性关节炎
中止
安慰剂
骨质疏松症
内科学
随机对照试验
临床试验
物理疗法
安慰剂对照研究
关节炎
双盲
替代医学
三苯氧胺
病理
癌症
乳腺癌
作者
Maryam Sahebari,Maryam Sarafraz Yazdi,Seyedeh Mehrnaz Aghili,Habibollah Esmaily,Sara Saeidi,Masoumeh Salari
出处
期刊:Current Rheumatology Reviews
[Bentham Science]
日期:2023-02-01
卷期号:19 (1): 93-101
标识
DOI:10.2174/1573397118666220518114415
摘要
The current study aimed to evaluate the effect of raloxifene on the disease activity of postmenopausal patients with rheumatoid arthritis (RA) and the prevention of glucocorticoid- induced osteoporosis.This double-blind, randomized clinical trial was conducted at the Rheumatic Diseases Research Center affiliated with Mashhad University of Medical Sciences from 2015 to 2016. Postmenopausal women with RA were randomly treated with raloxifene or placebo after discontinuation of alendronate. Disease activity was evaluated using DAS28ESR, HAQ, and VAS before and every two months after the intervention. In addition, bone mineral densitometry was performed for patients before and 14 months after the intervention. The disease activity and densitometric criteria were compared between the two groups at a significant level of p <0.05.A total of 17 patients were allocated to each group. The two groups were similar at baseline in underlying disease, age, duration of RA, duration of alendronate use, laboratory findings, and rheumatoid arthritis drugs. Moreover, the mean scores of DAS28ESR, HAQ, and VAS during visits were not significantly different between the intervention and control groups (p >0.05).The current study results could not prove any clinical benefits of adding raloxifene to standard therapies for patients with rheumatoid arthritis in improving their disease activity compared to placebo.Trial registration number is NCT02982083.
科研通智能强力驱动
Strongly Powered by AbleSci AI